Prenatal cell-free DNA (cfDNA) screening of chromosome abnormalities: A technical standard of the American College of Medical Genetics and Genomics (ACMG) and the College of American Pathologists (CAP)
Variant / mechanism
Analysis of trophoblast-derived fetal cell-free DNA in maternal plasma
Summary
A joint working group of the ACMG and the College of American Pathologists publishes a technical standard for laboratory validation and implementation of prenatal cell-free DNA (cfDNA) screening for chromosome abnormalities. The text recalls that ACMG, ACOG and SMFM recommend offering this screening as a first-tier option in all pregnancies, regardless of risk status, as it is the most sensitive and specific screening test for common fetal aneuploidies. Because fetal cfDNA originates from placental trophoblasts, it identifies fetuses at increased risk of trisomies 13, 18 and 21, sex chromosome aneuploidies and recurrent segmental aneuploidies associated with syndromes. The standard covers validation methods, ongoing monitoring of test quality and performance, and the interpretation and reporting of results.
Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.
Analysis
A text aimed first at laboratories, but useful to prescribers for understanding what a cfDNA screening result covers depending on the technique used. The abstract does not give the numerical thresholds adopted (fetal fraction, failure rate, expected performance): these must be read in the body of the standard before aligning a local procedure.
Analysis by Dr Thibaut Benquey
Why this score?
Clinical impact: 3/3 · Evidence strength: 2/3 · Novelty: 1/2 · Sample size: 0/1 · Publication status: 1/1 → Total: 7/10
Keywords
Every Wednesday · Annotated selection · Free · Unsubscribe anytime